Product Information
EVOXAC 30 MG CAPSULE is a brand product labeled by Cosette Pharmaceuticals, Inc., priced at $8.5909 per EA under NDC 00713088301. Its NADAC has been published 75 times since Mar 19, 2025.
FDA first approved this application on Jan 11, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the cevimeline hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Cosette Pharmaceuticals, Inc.NDC
00713088301
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA020989FDA Approved
1/11/2000
TE Code
AB
On Market Since
9/1/2022
Pharmacological Classes
Price Statistics
The NADAC for EVOXAC 30 MG CAPSULE has been published 75 times since Mar 19, 2025, and over the history we have for it it has risen 9.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.5909 per EA |
|---|---|
| All-time high | $8.5909 (Aug 19, 2026) |
| All-time low | $7.7614 (Sep 17, 2025) |
| 52-week high | $8.5909 |
| 52-week low | $7.7614 |
| Median price | $7.8081 |
| Average price | $7.8774 |
| Largest weekly change | +9.9% (Jul 8, 2026) |
| Weeks tracked | 75 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 92% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EVOXAC 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for EVOXAC 30 MG CAPSULE, manufactured by Cosette Pharmaceuticals, Inc., is $8.5909 per EA (NDC 00713088301), effective Aug 19, 2026.
How has the price of EVOXAC 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for EVOXAC 30 MG CAPSULE has risen 9.8%. It has been tracked across 75 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for EVOXAC 30 MG CAPSULE?
Since Mar 19, 2025, the NADAC for EVOXAC 30 MG CAPSULE has ranged from a low of $7.7614 (Sep 17, 2025) to a high of $8.5909 (Aug 19, 2026), with a median of $7.8081 per EA.
Are there cheaper alternatives to EVOXAC 30 MG CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CEVIMELINE HCL 30 MG CAPSULE, is $0.7080 per EA — about 92% below EVOXAC 30 MG CAPSULE.
Who manufactures EVOXAC 30 MG CAPSULE?
EVOXAC 30 MG CAPSULE (NDC 00713088301) is labeled by Cosette Pharmaceuticals, Inc., and CMS classifies it as a brand product.